Overview

A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma

Status:
NOT_YET_RECRUITING

Trial end date:
2030-06-30

Target enrollment:

Participant gender:

Summary

This is a prospective, multicenter, randomized, open-label phase 3 study evaluating the efficacy and safety of transarterial chemoembolization (TACE) combined with a triple oral cocktail regimen versus TACE combined with targeted therapy plus immunotherapy as first-line treatment for unresectable hepatocellular carcinoma (HCC).

Phase:

PHASE2

Details

Lead Sponsor:

Shanghai Zhongshan Hospital

Treatments:

apatinib
camrelizumab
Capecitabine
Pharmaceutical Preparations
Thalidomide